Denim Deal France sets stage for sustainable change in textile industry
The collaboration culminated in a formal agreement in 2020. The initiative's objectives include increasing the use of post-consumer recycled cotton, enhancing traceability, and encouraging sustainable production methods.
The Netherlands Embassy in Paris will host the inaugural event for Denim Deal France on 27 March 2025.
This event represents a significant opportunity to engage entities such as brands, sorting and collection agencies, recycling firms, weaving companies, and other critical components of the supply chain.
The launch event of Denim Deal France will focus on several key points including:
- The ambitions and commitments underlying the Denim Deal
- The advantages of joining the initiative and the prerequisites for participation
- Testimonials from participants in the Dutch Denim Deal
- Discussions with industry experts and leading figures
Denim, an enduring representation of fashion, now faces a significant challenge: minimising its environmental footprint and fully embracing a circular model.
The Denim Deal is committed to establishing a genuinely circular supply chain both within Europe and globally. It aims to produce over one billion jeans under this model by 2030.
To reach this milestone, the programme focuses on tangible commitments such as encouraging the integration of recycled cotton in new jeans manufacturing and enhancing product lifecycle traceability, minimising denim's environmental impact throughout its production process
It also seeks to prolong product lifespan to foster sustainable fashion.
Entities participating in the Denim Deal will have access to expert guidance on textile recycling, traceability, eco-design and to exclusive materials, webinars, and best practices.
They will also benefit from a network of dedicated members for sharing opportunities and innovations.
In addition, participants will gain from heightened visibility among consumers and business partners as well as a proactive stance on regulatory developments through collective strength.
"Denim Deal France sets stage for sustainable change in textile industry" was originally created and published by Just Style, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Target stock is down 64% over 4 years—and investors who were ‘hoping for an external CEO' are disappointed by the choice of its next leader
The news the retail industry has been anticipating for months was finally announced on Wednesday: Target CEO Brian Cornell is finally stepping down after 11 years at the helm and will be replaced by his operations chief Michael Fiddelke in February. But another piece of news the industry is looking for—Target returning to sales growth—will have to wait. Target reported yet another quarter of weak financial results, with comparable sales down 1.9%, and the cheap-chic retailer reaffirmed its expectation that sales will decline by a low single-digit percentage this year, projecting a third year in a row of declines. In recent years, after a torrid run that included Target making massive market share gains during the pandemic, the retailer has stagnated even as archrival Walmart has soared. Analysts say that Target has lost some of its magic touch. That is, the hip but affordable merchandise; fun, well-kept stores; and attentive customer service that helped it stand out and steal a lot of market share from rivals, notably department stores, in the not too distant past. 'Target, which used to be very attuned to consumer demand, has lost its grip on delivering for the American shopper,' Neil Saunders, managing director at GlobalData, wrote in a research note. Those problems have included a resurgence of out-of-stocks (a problem that was plaguing Target when Cornell took the reins in 2014 but had been overcome); long wait times at checkout registers; and what Saunders says are increasingly messy stores. Adding to Target's woes were its flip-flops on the DEI (diversity, equity, and inclusion) issue. The retailer attracted the ire of conservatives who threatened boycotts, but then angered many shoppers and employees when it curtailed some of its efforts. Fiddelke, who started at Target two decades ago and went on to become finance chief and then COO, acknowledged those problems on a call with reporters on Wednesday, according to CNBC. He has three main goals: reestablish the 'Tar-zhay' magic with customers, improve customer experience, and make better use of technology to make operations more efficient and less costly. He'll also have to rally the troops: The Wall Street Journal recently reported that a companywide survey in June found that 40% of Target workers didn't have confidence in its future. Though Fiddelke, 49, extolled the value of knowing Target deeply, shares fell 10% in morning trading on the news of his appointment. Citi analyst Paul Lejuez said investors were 'hoping for an external CEO' with fresh eyes. Meanwhile GlobalData's Saunders said Target needs a CEO who can cut through the groupthink he says has impeded innovation. Target's stock is down 64% since its all-time high four years ago. (During that time, Walmart shares have more than doubled.) Cornell, who took the reins in 2014, will stay on as executive chairman. For a number of years, Cornell was wildly successful in modernizing Target by integrating its e-commerce with its physical stores to turn it into a massive online player, upgrading its stores and overseeing teams that always seemed to know what fun items shoppers might want, with launch after launch of wildly popular store brands like Cat & Jack. Under Cornell, Target also successfully navigated the turmoil of the pandemic, with revenue rising from $78 billion in 2019 and peaking at $109.1 billion in 2022 before slipping ever since. (Meanwhile, Walmart, Costco, and Amazon continue to thrive.) It will be up to Fiddelke to figure out how to put the 'zhay' back in Target. This story was originally featured on Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Brokers risk falling behind as AI disruption accelerates
The majority of UK SMEs are comfortable with AI assessing their insurance needs and recommending the most suitable coverage options, according to GlobalData surveying. Meanwhile, AI-native insurance broker Meshed has secured backing from Aviva and other investors, with the aim of reshaping the commercial insurance market for SMEs. GlobalData's 2025 UK SME Insurance Survey has found that 64.5% of SMEs are comfortable, to some extent, with AI assessing their insurance needs and recommending the most suitable coverage options. Moreover, over a quarter of SMEs (26.7%) cited that they were extremely comfortable with this. How comfortable are you/would you be for an AI tool to do the following? 2025 Meanwhile, Meshed has raised £950,000 ($1.3m) in an oversubscribed pre-seed funding round to transform the commercial insurance market for SMEs. Investors included Haatch, Aviva via Founders Factory, the Exponential Science Foundation, and several angel backers. Meshed highlights that around 80% of UK SMEs remain underinsured, largely due to outdated brokerage practices and inefficient manual processes. By deploying AI-powered agents for quoting, data collection, and other routine tasks, the firm aims to cut administrative costs, reduce premiums, and enable brokers to focus more on client relationships and specialist advice. Yet, findings from our 2025 UK Commercial Insurance Broker Survey indicate that brokers may be underestimating the scale of disruption that AI could bring. Only 5.2% of brokers see AI as the biggest threat to their business, compared with 13.2% citing competition from other brokers and 11.2% from direct players. Moreover, adoption remains limited, with just 5.9% of brokers using AI-driven policy recommendation tools, while 78.6% report no plans to adopt them. Brokers should recognize that while AI may not seem like the greatest threat today, failing to adopt it could make it one tomorrow. By overlooking AI, brokers risk falling behind faster-moving competitors and losing relevance in a market where efficiency and digital capabilities increasingly drive client expectations. "Brokers risk falling behind as AI disruption accelerates" was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
2 days ago
- Yahoo
Trade-offs abound as big pharma makes direct-to-consumer transition
Novo Nordisk is the latest drugmaker to slash the price of a blockbuster medicine via its online platform amid drug pricing reforms in the US, but analysis shows a smooth transition to direct-to-consumer (DTC) channels will be tricky. US President Donald Trump has made reducing drug prices in the country one of his administration's key targets. He has spearheaded this goal with the Most Favoured Nation (MFN) policy, a legislative framework that would tie US drug prices to the lowest prices in other developed countries. As part of this push, Trump has urged pharmaceutical companies to embrace DTC business models. This includes companies establishing their own platforms or opting in to those from third parties that cut out middlemen, meaning final drug prices are lower. GlobalData's senior pharma strategic intelligence analyst Wafaa Hassan comments: 'The [DTC] development, closely tied to the administration's 'America First' healthcare agenda and its revived MFN pricing framework, marks a renewed phase of pressure on drugmakers to lower domestic prices while signalling alignment between the White House and the pharmaceutical industry.' Earlier this year, Novo Nordisk unveiled its DTC platform NovoCare Pharmacy with a heavily discounted price for weight loss drug Wegovy (semaglutide). Just this week, the drugmaker added type 2 diabetes treatment Ozempic (semaglutide) to the platform. Both drugs are available to cash-paying patients for $499 each for a monthly supply. The list price of both drugs in the US sits at around $1,300 per month. While the move to discount the two drugs is more likely a response to the popularity of cheaper compounded alternatives, Trump will nevertheless be pleased with Novo's decision. Ozempic – a drug that generated global sales of $10bn in Q2 this year alone – being available for cheaper on a DTC platform is a coup Trump will likely point to in the face of criticism for his pricing reforms. However, challenges such as a limited patient awareness and disruption to traditional distribution channels could hinder the adoption of the DTC models by pharma companies, according to analysis by GlobalData. Hassan adds: 'From a drugmaker perspective, more challenges will occur following the initiatives, such as new operational demands, margin pressure and potential friction with insurers. The likelihood of success will only depend on how well the pharma industry navigates these trade-offs in the upcoming months.' Novo is far from the only big pharma company bolstering DTC medicine offerings. Novo's main rival in the GLP-1RA arena, Eli Lilly, has also conducted similar moves. The company began offering its weight loss medication Zepbound (tirzepatide) to self-paying patients at a steep discount on its own DTC platform LillyDirect in 2024. Taking a page from the two GLP-1RA developers, Bristol Myers Squibb (BMS) and Pfizer also established a DTC online programme for their blockbuster blood thinner Eliquis (apixaban) in July. BMS, Pfizer, Eli Lilly, and Novo Nordisk were among 17 pharma companies to receive a letter from Trump requesting more steps be taken by them to cut drug prices. "Trade-offs abound as big pharma makes direct-to-consumer transition" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
